Back to Search Start Over

Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

Authors :
Salmanton-García, Jon
Seidel, Danila
Koehler, Philipp
Mellinghoff, Sibylle
Herbrecht, Raoul
Klimko, Nikolai
Ráčil, Zdeněk
Falces-Romero, Iker
Ingram, Paul
Benítez-Peñuela, Miguel-Ángel
Rodríguez, José Yesid
Desoubeaux, Guillaume
Barać, Aleksandra
García-Vidal, Carolina
Hoenigl, Martin
Mehta, Sanjay
Cheng, Matthew
Klyasova, Galina
Heinz, Werner
Iqbal, Nousheen
Krause, Robert
Ostermann, Helmut
Penack, Olaf
Schalk, Enrico
Sheppard, Donald
Willinger, Birgit
Wisplinghoff, Hilmar
Vehreschild, J Janne
Cornely, Oliver
Vehreschild, Maria
Khedr, Reham Abdelaziz
Arencibia-Núñez, Alberto
Avilés-Robles, Martha
Banke, Ingo
Basher, Ariful
Benachinamardi, Keertilaxmi
Bertz, Harmut
Chakrabarti, Arunaloke
Drgona, Lubos
García-Martínez, Jesús
García-Rodríguez, Julio
Gräber, Sandra
Härter, Georg
Klein, Michael
Kouba, Michal
Lee, Dong-Gun
Le Govic, Yohann
Leo, Fabian
Maertens, Johan
Maschmeyer, Georg
Meintker, Lisa
Mo, Xiao-Dong
Müller, Lena-Katharina
Müller, Nicolas
Nel, Jeremy Stephen
Novák, Jan
Patel, Atul
Pfäfflin, Frieder
Pozo-Laderas, Juan-Carlos
Puerta-Alcalde, Pedro
Rodríguez-Guardado, Azucena
Schroers, Roland
Shekar, Vandana
Shenoi, Susan
Silling, Gerda
Vinh, Donald
Waizel-Haiat, Salomón
Yee Yee, Mandy Yap
Prakash, Peralam Yegneswaran
Žák, Pavel
Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP)
Université d'Angers (UA)
Service d'Hématologie
CHU Strasbourg
Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR)
Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Department of Medicine
Medical University Graz
Schwerpunkt Infektiologie, Medizinische Klinik und Poliklinik II
Universitätsklinikum Würzburg
Department of Haematology and Oncology, Medical Clinic III
University Hospital Munich—Großhadern, Ludwig Maximilian University
Klinik für Hämatologie und Onkologie
Charité, Campus Benjamin Franklin
Department of Haematology/Oncology
Magdeburg University Hospital
McGill University = Université McGill [Montréal, Canada]
Medizinische Universität Wien = Medical University of Vienna
University Hospital of Cologne [Cologne]
Postgraduate Institute of Medical Education and Research
Laboratoire de psychologie cognitive (LPC)
Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)
Anofel Cryptosporidium National Network
Department of Hematology
University Hospital Gasthuisberg
Medizinische Klinik, Hämatologie und Onkologie
Klinikum Ernst von Bergmann
Real Expression Artificial Life (IRIT-REVA)
Institut de recherche en informatique de Toulouse (IRIT)
Université Toulouse 1 Capitole (UT1)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3)
Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP)
Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse 1 Capitole (UT1)
Université Fédérale Toulouse Midi-Pyrénées
Medizinische Klinik A des Universitätsklinikums Münster
Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)
University Hospital Gasthuisberg [Leuven]
Université Toulouse Capitole (UT Capitole)
Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J)
Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3)
Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP)
Université de Toulouse (UT)-Toulouse Mind & Brain Institut (TMBI)
Université Toulouse - Jean Jaurès (UT2J)
Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3)
Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole)
Université de Toulouse (UT)
Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)
Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)
Source :
Journal of Antimicrobial Chemotherapy, Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (11), pp.3315-3327. ⟨10.1093/jac/dkz344⟩, Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, Journal of Antimicrobial Chemotherapy, 74 (11), pp.3315-3327. ⟨10.1093/jac/dkz344⟩, Journal of Antimicrobial Chemotherapy, 2019, Journal of Antimicrobial Chemotherapy, 74 (11), pp.3315-3327. ⟨10.1093/jac/dkz344⟩
Publication Year :
2019
Publisher :
Oxford University Press (OUP), 2019.

Abstract

Background First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. Objectives Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. Methods We performed a case-matched analysis with proven or probable IM patients from the FungiScope® Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). Results Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n = 4/5) of patients receiving 1st-POSnew, for 27.8% (n = 5/18) receiving 1st-AMB+POSnew and for 50.0% (n = 11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n = 1/5) in 1st-POSnew versus 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew versus 52.0% (n = 26/50) in 1st-AMB; and 0.0% (n = 0/22) in SAL-POSnew versus 4.4% (n = 2/45) in SAL-POSsusp]. Conclusions Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.

Details

ISSN :
14602091 and 03057453
Volume :
74
Database :
OpenAIRE
Journal :
Journal of Antimicrobial Chemotherapy
Accession number :
edsair.doi.dedup.....f7aca142c2d95049170f5ec0a06400de